ketoconazole has been researched along with selegiline in 9 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (11.11) | 18.2507 |
| 2000's | 5 (55.56) | 29.6817 |
| 2010's | 3 (33.33) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL | 1 |
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Choi, SS; Contrera, JF; Hastings, KL; Kruhlak, NL; Sancilio, LF; Weaver, JL; Willard, JM | 1 |
| Ambroso, JL; Ayrton, AD; Baines, IA; Bloomer, JC; Chen, L; Clarke, SE; Ellens, HM; Harrell, AW; Lovatt, CA; Reese, MJ; Sakatis, MZ; Taylor, MA; Yang, EY | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Kintzer, PP; Peterson, ME | 1 |
| Frosini, M; Fusi, F; Pessina, F; Sgaragli, GP; Tipton, KF; Valoti, M | 1 |
| Anttila, M; Karnani, H; Nyman, L; Pelkonen, O; Salonen, JS; Taavitsainen, P | 1 |
| Peterson, ME | 1 |
3 review(s) available for ketoconazole and selegiline
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
Medical treatment of pituitary-dependent hyperadrenocorticism in dogs.
Topics: Animals; Bromocriptine; Cushing Syndrome; Cyproheptadine; Dog Diseases; Dogs; Drug Administration Schedule; Ketoconazole; Mitotane; Selegiline | 1994 |
Medical treatment of canine pituitary-dependent hyperadrenocorticism (Cushing's disease).
Topics: Animals; Antifungal Agents; Cushing Syndrome; Dog Diseases; Dogs; Dose-Response Relationship, Drug; Drug Administration Schedule; Ketoconazole; Mitotane; Monoamine Oxidase Inhibitors; Pituitary Diseases; Pituitary Gland; Selegiline; Treatment Outcome | 2001 |
6 other study(ies) available for ketoconazole and selegiline
| Article | Year |
|---|---|
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Drug Prescriptions; Drug-Related Side Effects and Adverse Reactions; Endpoint Determination; Models, Molecular; Quantitative Structure-Activity Relationship; Software; United States; United States Food and Drug Administration | 2004 |
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.
Topics: | 2008 |
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
Topics: Chemical and Drug Induced Liver Injury; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Decision Trees; Drug Evaluation, Preclinical; Drug-Related Side Effects and Adverse Reactions; Glutathione; Humans; Liver; Pharmaceutical Preparations; Protein Binding | 2012 |
Cytochrome P450-dependent N-dealkylation of L-deprenyl in C57BL mouse liver microsomes: effects of in vivo pretreatment with ethanol, phenobarbital, beta-naphthoflavone and L-deprenyl.
Topics: Animals; beta-Naphthoflavone; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Disulfiram; Enzyme Induction; Enzyme Inhibitors; Ethanol; Fomepizole; In Vitro Techniques; Isoenzymes; Ketoconazole; Mice; Mice, Inbred C57BL; Microsomes, Liver; Monoamine Oxidase Inhibitors; NADH, NADPH Oxidoreductases; NADPH-Ferrihemoprotein Reductase; Phenobarbital; Pyrazoles; Selegiline | 2000 |
Selegiline metabolism and cytochrome P450 enzymes: in vitro study in human liver microsomes.
Topics: Amphetamines; Aryl Hydrocarbon Hydroxylases; Cytochrome P-450 CYP2C19; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Fluvoxamine; Humans; Ketoconazole; Methamphetamine; Microsomes, Liver; Mixed Function Oxygenases; Monoamine Oxidase Inhibitors; Selegiline; Theophylline | 2000 |